Business Wire

NIPPON KINZOKU: New Launch of “STA Finish” Stainless Steel for High-Precision Etching as an “Eco-Product”

21.8.2025 03:01:00 CEST | Business Wire | Press Release

Share

NIPPON KINZOKU CO., LTD. (Headquarters: Minato-ku, Tokyo) is pleased to announce the launch of its fourth environmentally-friendly “Eco-Product” series, STA (Special Tension Annealing) finish stainless steel, which eliminates warping and refines crystal grain size for high-definition etching.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250820626946/en/

Conventional TA (Tension Annealing) finish has been highly evaluated as a stainless spring material with excellent flatness, low residual stress, and dimensional stability after processing. STA finish, which is a further evolution of this finish, minimizes residual stress and is optimized for etching processing.

In the etching process, particularly in the half-etching process, spring material warping has been an issue. STA finish greatly reduces this warping, dramatically improving dimensional stability.

Furthermore, in response to demand for smoother etched surfaces, we have achieved finer crystal grain sizes. This makes the product suitable for high-precision microfabrication applications.

These characteristics enable process elimination and simplification, contributing to improved energy efficiency and reduced environmental impact throughout your manufacturing process. Additionally, greater product design flexibility enables the optimization of shapes and specifications, thereby contributing to improved processing efficiency and yield.

Leveraging these characteristics, our product has been widely adopted in various applications, including smartphone components, metal masks, and wrapping carriers.

Therefore, we have certified STA finish as an “Eco-Product” from these perspectives. We are working to achieve net zero CO2 emissions by 2050 and are engaged in sustainable manufacturing through the widespread use of environmentally friendly materials.

In addition, this product is in line with our 11th management plan, “NIPPON KINZOKU 2030,” and is a unique product that meets customer needs with the keyword “Near Net Performance” (achieving the performance required of the final product with the material). We aim to further expand sales in fields such as 5G communications, mobile devices, and semiconductor-related products.

Features

  1. The material undergoes heat treatment and shape correction simultaneously, resulting in excellent flatness.
  2. Internal stress (distortion) accumulated during processing is minimized to the utmost, making it ideal for applications requiring high processing accuracy.
  3. As an option, products with a refined grain size, which allows for a smoother etching surface, are also available.
    https://www.nipponkinzoku.co.jp/assets/images/2025/08/Examples-of-Cross-Sectional-Photographs-after-Etching.png

Specifications
1) Steel Grade: SUS304, SUS301, SUS430, etc.
2) Thickness: 0.1–0.5 mm
3) Width: Maximum 600 mm
* Fine-Grained Material is available only for SUS304.

Click here for more details.
https://www.nipponkinzoku.co.jp/assets/images/2025/08/New-Launch-of-STA-Finish-Stainless-Steel-for-High-Precision-Etching-as-an-Eco-Product.pdf

About NIPPON KINZOKU Group
Our products have been used in a range of areas from the precision field to the construction industry. https://www.nipponkinzoku.co.jp/en/

View source version on businesswire.com: https://www.businesswire.com/news/home/20250820626946/en/

Contacts

Production Process & Support Dept.
NIPPON KINZOKU CO., LTD.
Email: sisaku-sc@nipponkinzoku.co.jp
https://www.nipponkinzoku.co.jp/en/inquiry -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.nipponkinz
oku.co.jp%2Fen%2Finquiry&esheet=54310078&newsitemid=20250820626946&lan=en-US&anc
hor=https%3A%2F%2Fwww.nipponkinzoku.co.jp%2Fen%2Finquiry&index=4&md5=cd199f3d85f
dc3bb5d2b554e725b0b33

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye